FAQ’s about RELYVRIO (AMX0035)
On 9/29/2022, the US Food and Drug Administration’s (FDA) announced that it approved RELYVRIO (AMX0035) as a new treatment for ALS.
As we celebrate this ground-breaking development in the fight against ALS, we want to thank everyone who worked tirelessly to make this monumental moment happen! While we still have a lot of work to find cures for ALS, this new treatment is a significant step toward our ultimate goal.
We know that there are a lot of questions that people have, in light of this exciting news. Here are answers to some of the frequently asked questions that we are fielding from our ALS community.
Amylyx is working on making RELYVRIO available as soon as possible. We encourage you to talk with your doctor, and learn more on the website or contact the Amylyx Care Team (ACT) at 1-866-318-2989. The ALS Network will continue to provide the very latest information as it becomes available.
Our deepest gratitude to the entire ALS community for your advocacy efforts and to everyone living with ALS who participated in the clinical trials that led to this historic milestone.